You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Local Advanced/Metastatic

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Solid Tumor, Adult, EphA2 Overexpression, KRAS G12V Trial in Beijing (KRAS-EphA-2-CAR-DC, Abraxane, Cyclophosphamide)

Recruiting
  • Solid Tumor, Adult
  • +4 more
  • KRAS-EphA-2-CAR-DC
  • +3 more
  • Beijing, Beijing, China
    Biotherapeutic Department of Chinsese PLA Gereral Hospital
Nov 29, 2022

Advanced Urothelial Carcinoma Trial in Beijing (9MW2821, Toripalimab)

Not yet recruiting
  • Advanced Urothelial Carcinoma
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Oct 9, 2023

Breast Cancer Trial (HRS-1358)

Not yet recruiting
  • Breast Cancer
  • (no location specified)
Nov 17, 2022

Solid Tumor, Adult, Lymphoma, EphA2 Overexpression Trial in Beijing (TP53-EphA-2-CAR-DC, Abraxane, Cyclophosphamide)

Recruiting
  • Solid Tumor, Adult
  • +6 more
  • TP53-EphA-2-CAR-DC
  • +3 more
  • Beijing, Beijing, China
    Biotherapeutic Department of Chinsese PLA Gereral Hospital
Nov 29, 2022

Thyroid Cancer Trial in Peking (Apatinib)

Completed
  • Thyroid Cancer
  • Peking, China
    Peking Union Medical College Hospital
Jan 18, 2022

Gastric Cancer Trial in Beijing (RC48-ADC, Herceptin, Toripalimab)

Not yet recruiting
  • Gastric Cancer
  • Beijing, China
    Beijing Cancer Hospital
Aug 7, 2023

Metastatic or Local Advanced Breast Cancer of Patients Trial in Beijing, Changchun (HRS-8080 tablets?SHR 6390

Enrolling by invitation
  • Metastatic or Local Advanced Breast Cancer of Patients
  • HRS-8080 tablets、SHR 6390 tablets、Abemaciclib、Everolimus
  • Beijing, Beijing, China
  • +1 more
Apr 2, 2022

NSCLC Trial in Worldwide (Repotrectinib, Crizotinib)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Augusta, Georgia
  • +40 more
Nov 29, 2023

NSCLC Trial in Worldwide (Nivolumab)

Completed
Has Results
  • Non-Small Cell Lung Cancer
  • Nivolumab
  • Birmingham, Alabama
  • +16 more
Dec 1, 2022

Advanced or Metastatic NSCLC Trial in Moscow, Saint Petersburg, St. Petersburg (Ceralasertib, Durvalumab)

Recruiting
  • Advanced or Metastatic NSCLC
  • Moscow, Russian Federation
  • +7 more
Jul 4, 2023

HER2 Positive Advanced Solid Tumors Trial (HypoSti.CAR-HER2 T cells, Albumin-bound paclitaxel, Cyclophosphamide)

Not yet recruiting
  • HER2 Positive Advanced Solid Tumors
  • HypoSti.CAR-HER2 T cells
  • +2 more
  • (no location specified)
Jan 12, 2023

NSCLC Trial in Worldwide (Nivolumab, Docetaxel)

Active, not recruiting
Has Results
  • Non-Small Cell Lung Cancer
  • Beijing, Beijing, China
  • +31 more
Jul 21, 2022

Advanced Solid Tumor, Metastatic Solid Tumor, NSCLC Trial in Suwon-si, Daejeon, Seoul (GI-101, Pembrolizumab, Lenvatinib)

Recruiting
  • Advanced Solid Tumor
  • +7 more
  • Suwon-si, Kyeonggi-do, Korea, Republic of
  • +3 more
Apr 19, 2022

Locally Advanced Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer Trial in France (SRT, Immunotherapy)

Recruiting
  • Locally Advanced Non Small Cell Lung Cancer
  • Metastatic Non Small Cell Lung Cancer
  • Angers, France
  • +4 more
Apr 21, 2022

Nivolumab Plus Ipilimumab in Renal Cell Cancer in Real World

Active, not recruiting
  • Advanced or Metastatic Renal Cell Carcinoma
    • Tokyo, Japan
      Local Institution - 0001
    May 25, 2022

    Gastric Cancer, HER2 Overexpressing Gastric Carcinoma Trial in Beijing (RC48-ADC)

    Completed
    • Gastric Cancer
    • HER2 Overexpressing Gastric Carcinoma
    • Beijing, Beijing, China
      Beijing Cancer Hospital
    Jan 12, 2022

    Carcinoma, Hepatocellular Trial in Worldwide (Relatlimab, Nivolumab, Bevacizumab)

    Recruiting
    • Carcinoma, Hepatocellular
    • Los Angeles, California
    • +62 more
    Feb 1, 2023

    Advanced Cancer Trial in Kashiwa-shi, Kobe-shi (Lirilumab, Nivolumab, Ipilimumab)

    Completed
    • Advanced Cancer
    • Lirilumab
    • +2 more
    • Kashiwa-shi, Chiba, Japan
    • +1 more
    Mar 9, 2022

    NSCLC Trial in Worldwide (Nivolumab)

    Completed
    Has Results
    • Non-Small Cell Lung Cancer
    • Wels, Oberösterreich, Austria
    • +89 more
    Oct 17, 2022

    Nivolumab Plus Chemotherapy in First Line Treatment of Adult

    Recruiting
    • Gastric Cancer
      • Hamburg, Germany
        Local Institution
      Feb 24, 2022

      Nivolumab in Advanced/Metastatic Non-Small Cell Lung Cancer

      Completed
      • Non-Small Cell Lung Cancer
        • Minato-ku, Tokyo, Japan
          Local Institution
        Jan 20, 2022

        Melanoma Trial in Worldwide (Relatlimab, Ipilimumab)

        Active, not recruiting
        • Melanoma
        • Tucson, Arizona
        • +29 more
        Dec 13, 2022

        Renal Cell Carcinoma Trial in Worldwide (Nivolumab, Bempegaldesleukin, Axitinib)

        Active, not recruiting
        • Renal Cell Carcinoma
        • Nivolumab
        • +2 more
        • Springdale, Arkansas
        • +33 more
        Nov 22, 2022

        Pan Tumor Trial in Worldwide (Nivolumab, Ipilimumab)

        Active, not recruiting
        • Pan Tumor
        • Nivolumab
        • Ipilimumab
        • Santa Monica, California
        • +59 more
        Jul 26, 2022

        Nivolumab Monotherapy or in Combination With Ipilimumab in

        Active, not recruiting
        • Melanoma
          • Essen, Germany
            Local Institution
          Apr 25, 2022